The US Rx-to-OTC switch market likely will attract dermatology entries for treatment categories other than acne, the indication for the recently approved Differin Gel, says Laura Mahecha, Kline & Co.'s health care industry manager.
Dermatology OTC Switches Loom Next For Consumer Health Growth
Dermatology OTC switch products for acne, eczema and psoriasis are likely to emerge, says Kline analyst Laura Mahecha. Switches, the return of recalled OTC brands and market consolidation drove a 4.2% increase for the US consumer health market in 2015.